Amgen (AMGN)
(Delayed Data from NSDQ)
$298.43 USD
+6.43 (2.20%)
Updated Oct 31, 2025 04:00 PM ET
After-Market: $298.50 +0.07 (0.02%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
AMGN 298.43 +6.43(2.20%)
Will AMGN be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for AMGN based on the 1-3 month trading system that more than doubles the S&P 500.

Zacks News for AMGN
Demographic Megatrend: Stocks Poised to Benefit From Global Aging
Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know
AMGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Amgen (AMGN) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
Amgen's Q3 Earnings in the Cards: Here's What to Expect
Analysts Estimate Acadia Pharmaceuticals (ACAD) to Report a Decline in Earnings: What to Look Out for
Other News for AMGN
Earnings Scorecard: 24 out of 25 healthcare firms deliver EPS wins this week
Palantir, Qualcomm Set To Report Earnings
Crossed Above 20 Day Moving Average appears for AMGN after 2.2% move
More than 80% of companies report EPS wins this week: Earnings Scorecard
AbbVie: Why Q3 Confirms Its Immunology Dominance